Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, develops and manufactures a wide range of pharmaceuticals for human and animal use. In addition, it offers contract manufacturing services through Boehringer Ingelheim BioXcellence, which operates production facilities in Biberach, Germany; Vienna, Austria; Shanghai, China; and Fremont, the US. Its pipeline encompasses candidates for the treatment of chronic obstructive pulmonary disease (COPD), Crohn’s disease, congestive heart failure, acute respiratory distress syndrome, idiopathic pulmonary fibrosis (IPF), and systemic sclerosis with interstitial lung disease (SSc-ILD), among others. The company portfolio includes products for pets and horses as well as livestock, swine, ruminants and poultry.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Boehringer Ingelheim's R&D arm focuses on researching and developing first-in-class breakthrough medicines that address high medical needs in areas such as oncology, regenerative medicine, autoimmunity, and antimicrobial resistance. The company invests significantly in preclinical biotech companies through the Boehringer Ingelheim Venture Fund and collaborates with over 200 partners to expand its R&D portfolio. In FY2025, the company continued to advance its innovation-driven strategy by forming new partnerships in eye health, autoimmune diseases, and oncology, leveraging cutting-edge technologies and novel therapeutic approaches. The R&D activities of Boehringer Ingelheim are managed through its global research networks for Human Pharma and Animal Health. These units are responsible for driving the continued expansion and renewal of the company's product portfolio, laying the foundations for long-term growth. The Boehringer Ingelheim Venture Fund also plays a crucial role in investing in innovative preclinical biotech companies. Boehringer Ingelheim operates R&D centers across eight countries: Germany, the US, Austria, Japan, France, the Netherlands, Switzerland, and China. The company has formed major technology alliances with partners such as Google, the University of Toronto, QC Ware Corp., PsiQuantum Corp., Re-Vana Ltd., AimedBio Inc., Synaffix B.V., Cue Biopharma Inc., CDR-Life AG, and Kyowa Kirin Ltd. In FY2025, the company spent EUR6,353 million on its R&D activities, which as a percentage of revenue stood at 22.9%, and grew 2% YoY. The company has established more than 130 research partnerships and is involved in significant technology alliances.